Keywords regulatory T cells CTLA-4 prostate cancer neoadjuvant immunotherapy CyTOF single-cell RNA sequencing tumor-associated macrophages dendritic cells Introduction To date, immune checkpoint blockade immunotherapy (ICB) has proven largely ineffective for patients with prostate cancer (PCa).1,2,3 Agents targeting the PD-1/PD-L1 pathway alone or in combination with androgen receptor inhibitors,4,5,6 chemotherapy,7 or PARP inhibition8 have failed in phase III trials.9 Similarly, CTLA-4...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Grace
Contact Grace, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack